Retention [Regulatives / Guidelines]

posted by Vuas – India, 2021-03-05 19:02 (42 d 12:11 ago) – Posting: # 22248
Views: 618

Hi everyone,
Some dosage forms like buccal tablets, rectal suppositories are not listed in Table -1 and 2 of Compliance Policy for the Quantity of Bioavailability and Bioequivalence Samples Retained Under 21 CFR 320.38(c). However as per note:11, can we proceed for minimum sample retention quantity of 30 units each for test and reference products? Thanks in advance

Edit: Guidance linked. [Helmut]

Complete thread:

 Admin contact
21,419 posts in 4,475 threads, 1,509 registered users;
online 18 (0 registered, 18 guests [including 3 identified bots]).
Forum time: Saturday 08:13 CEST (Europe/Vienna)

I never did anything worth doing by accident,
nor did any of my inventions come by accident;
they came by work.    Thomas Alva Edison

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz